Martin Berman-Gorvine

Will investors see the company's breakthrough to profitability in 2023?

With net earnings of $20 billion last year and almost $70 billion in cash and cash equivalents, UnitedHealth seems well-positioned for further growth.

Has the company bitten off more than it can chew in R&D, or will its depression drug launch it into the stratosphere?

Its market dominance in diabetes drugs that also help with weight loss is set to continue for at least the next few years.

EDIT-301 had positive clinical results in treating sickle cell disease, but the potential payoff is still years in the future.

New treatments for various cancers, eye diseases, and more may bring in future revenues.

Behavioral health offerings could be the answer for Universal Health Services' future growth.

The stand-alone company that spun off from GE in January is off to a good start.

Is Florida sunshine the cure for what ails Green Thumb?

Elevance touts a growing customer base.

The French drug company got the nod for a hemophilia treatment.

Cancer-causing toxic particles are a significant problem for the Netherlands-based firm.

The current drop in 2023 sales likely won't matter in the long term.

The company is doubling down on its vaccine success.

Clorox may not be nimble enough to take advantage of the demand opportunity that came its way during the pandemic. But there's more to like about the business.